McKesson Crosses $1,000 as Shorts Retreat

McKesson has crossed the $1,000 mark for the first time, trading at $999.62 after a 10.8% gain over the past month, while the short position against it has moved in the opposite direction, falling 15.8% over the same period to 1.8% of the free float.

The retreat in short interest is the clearest signal in the positioning data. Shares short have dropped from roughly 2.75 million in early October to 2.22 million now, a steady unwind that tracks almost perfectly with the stock's climb. Borrow costs are equally relaxed, running at 0.36% annually, down 11% over the past month. Availability is effectively unlimited, with the lending pool carrying far more shares than are currently borrowed, leaving no mechanical pressure on the short side from supply constraints. The put/call ratio at 0.82 sits a little above its 20-day average of 0.80, a modest tilt toward hedging, but nothing that changes the broader picture of a market leaning long into this name.

The Street broadly agrees on the direction. UBS raised its target to $1,200 in mid-October while keeping its Buy rating, the most aggressive public call in the recent batch. Mizuho lifted its target to $1,020, though it remained at Neutral. Leerink Partners bumped its Outperform target to $1,070. The mean analyst target is $1,026, sitting just above the current price, which reflects targets set before the most recent leg of the rally rather than a fully re-rated consensus. The bull case rests on McKesson's dominant position in pharmaceutical wholesaling and the structural shift toward specialty drugs, expected to account for more than 55% of total drug spending by 2028. Bears focus on GLP-1 exposure, with prior authorisation revenue estimated at $560 million to $660 million, and on the 2028 Medicare drug price negotiations, which could apply 40% to 60% price cuts across roughly $28 billion of drug spend where McKesson operates at thin margins. The PE multiple has expanded to 20.1x, up from 18.6x a month ago, as the stock has re-rated faster than earnings estimates.

One piece of colour worth noting: retail attention to McKesson has spiked relative to its own recent history. Wikipedia views carry a z-score of 2.95 against the company's own trailing 90 days, the highest attention reading in the dataset window. That is an attention signal, not a revenue indicator, but the spike aligns with the stock's approach to the round-number $1,000 level and earnings day on November 4.

Insider activity has not changed character since the previous note. The most recent trade was a planned sale by the EVP and CIO/CTO on October 15 for roughly $797,000, executed under a 10b5-1 schedule. Net insider selling over 90 days amounts to about $1.2 million across a small number of transactions, all plan-driven. No open-market buying has appeared as the stock climbed from the $760s to $1,000. Closest peers COR and CAH both gained on the week, up 4.7% and 2.6% respectively, suggesting the drug distribution group moved broadly in the same direction rather than McKesson outrunning a sector rotation.

The next data point that matters is the fiscal second-quarter earnings release, with figures due today after the close.